In 2Q26, Burcon advanced commercialization across multiple proteins at the Galesburg facility, achieving first commercial production and sales of Puratein® C canola protein and first commercial production of FavaPro™ fava protein, while continuing to scale Peazazz® C pea protein. Subsequent to quarter-end, the Company received more than $500,000 in commercial sales orders and recorded the first commercial sale of FavaPro, signaling growing demand as customers complete evaluations and move to purchase orders. This operational flexibility positions the Company to meet evolving customer needs quickly and with consistent quality.